Literature DB >> 18055327

Guidelines for the detection and treatment of liver metastases of colorectal cancer.

A Abad1, J Figueras, C Valls, A Carrato, F Pardo, E Díaz-Rubio, E Aranda.   

Abstract

The spread of the surgical treatment for hepatic metastases have been crucial in the improvement of treatment and survival of metastatic colorectal cancer. The early and accurate diagnosis of metastases and the assessment of their size are essential factors to reach the optimal results with this treatment strategy. The precise indication of the surgical technique with or without the previous administration of neoadjuvant chemotherapy is of significant importance for the choice of R0 surgery and the timing of intervention. Although there is an agreement regarding some parameters related to diagnosis techniques and surgical criteria such as the bilobar extension, the size of the remaining liver post-surgical removal and the indication of pre-operatory chemotherapy, it is necessary to consider all these factors to set up standard criteria and optimize the results. In this article we review all these parameters, from disease follow up to detect metastatic dissemination to the basic criteria for use of neoadjuvant chemotherapy, in order to suggest some general recommendations of evidence level II and recommendation grade A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055327     DOI: 10.1007/s12094-007-0129-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  34 in total

1.  ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer.

Authors: 
Journal:  Ann Oncol       Date:  2001-08       Impact factor: 32.976

2.  Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.

Authors:  J Figueras; C Valls; A Rafecas; J Fabregat; E Ramos; E Jaurrieta
Journal:  Br J Surg       Date:  2001-07       Impact factor: 6.939

3.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.

Authors:  Lee M Ellis; Steven A Curley; Axel Grothey
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

4.  Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis.

Authors:  J Ward; K S Naik; J A Guthrie; D Wilson; P J Robinson
Journal:  Radiology       Date:  1999-02       Impact factor: 11.105

5.  Detection of hepatic metastases using ferucarbotran-enhanced MR imaging: feasibility and diagnostic accuracy of three-dimensional sensitivity-encoding water-excitation multishot echo-planar sequence (3D-SWEEP).

Authors:  Kensaku Mori; Nobuyuki Takahashi; Makiko Hiratsuka; Masanari Shiigai; Manabu Minami; Tatsuya Oda; Nobuhiro Ohkohchi; Yukio Morishita
Journal:  J Magn Reson Imaging       Date:  2006-11       Impact factor: 4.813

6.  Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline.

Authors:  Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

7.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Authors:  G Folprecht; A Grothey; S Alberts; H-R Raab; C-H Köhne
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

8.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

9.  Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis.

Authors:  Shandra Bipat; Maarten S van Leeuwen; Emile F I Comans; Milan E J Pijl; Patrick M M Bossuyt; Aeilko H Zwinderman; Jaap Stoker
Journal:  Radiology       Date:  2005-08-11       Impact factor: 11.105

Review 10.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

Authors:  R Adam
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

View more
  6 in total

1.  Synchronous isolated adrenal metastasis from rectum adenocarcinoma.

Authors:  Teresa Bonfill; Emma Dotor; Anna Darnell; Alex Casalots; Jordi Bombardó; Eugeni Saigí; Carles Pericay
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.405

Review 2.  Outcome quality standards for surgery of colorectal liver metastasis.

Authors:  Manuel Bellver Oliver; Javier Escrig-Sos; Fernando Rotellar Sastre; Ángel Moya-Herráiz; Luis Sabater-Ortí
Journal:  Langenbecks Arch Surg       Date:  2020-06-23       Impact factor: 3.445

3.  Genetic predisposition to high anxiety- and depression-like behavior coincides with diminished DNA methylation in the adult rat amygdala.

Authors:  Chelsea R McCoy; Nateka L Jackson; Jeremy Day; Sarah M Clinton
Journal:  Behav Brain Res       Date:  2016-12-11       Impact factor: 3.332

Review 4.  A systematic review of treatment guidelines for metastatic colorectal cancer.

Authors:  M S Edwards; S D Chadda; Z Zhao; B L Barber; D P Sykes
Journal:  Colorectal Dis       Date:  2012-02       Impact factor: 3.788

5.  Metachronous bilateral isolated adrenal metastasis from rectal adenocarcinoma: a case report.

Authors:  H Jabir; N Tawfiq; M Moukhlissi; M Akssim; A Guensi; B Kadiri; Z Bouchbika; A Taleb; N Benchekroun; H Jouhadi; S Sahraoui; S Zamiati; A Benider
Journal:  Case Rep Gastrointest Med       Date:  2014-04-22

6.  Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer.

Authors:  Yingqiang Wang; Qianqian Luo; Youping Li; Haiqing Wang; Shaolin Deng; Shiyou Wei; Xianglian Li
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.